MX9503070A - Sistema de expresion que utiliza proteinas de fusion autolisables y un polipeptido de reduccion novedoso. - Google Patents

Sistema de expresion que utiliza proteinas de fusion autolisables y un polipeptido de reduccion novedoso.

Info

Publication number
MX9503070A
MX9503070A MX9503070A MX9503070A MX9503070A MX 9503070 A MX9503070 A MX 9503070A MX 9503070 A MX9503070 A MX 9503070A MX 9503070 A MX9503070 A MX 9503070A MX 9503070 A MX9503070 A MX 9503070A
Authority
MX
Mexico
Prior art keywords
protease gene
virus protease
yellow vein
vein virus
gln
Prior art date
Application number
MX9503070A
Other languages
English (en)
Inventor
Tohru Takahashi
Nobufusa Serizawa
Ryuta Koishi
Ichiro Kawashima
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP30380994A external-priority patent/JP3337178B2/ja
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of MX9503070A publication Critical patent/MX9503070A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Abstract

La presente invencion provee sistemas de expresion para polipéptidos exogenos en donde el polipéptido se expresa como una proteína de fusion junto con Inclusion Nuclear a del virus de la nervadura amarilla del trébol (NIa), el componente de NIa sirviendo para autorizar la proteína de fusion después de la expresion. Este sistema se puede usar para expresar un polipéptido novedoso que se ha designado KM31-7 y que es capaz de reducir dicloroindofenol y glutation reducido. Este polipéptido es util en el tratamiento de trastornos causados por tension oxidativa.
MX9503070A 1994-07-13 1995-07-13 Sistema de expresion que utiliza proteinas de fusion autolisables y un polipeptido de reduccion novedoso. MX9503070A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP16105394 1994-07-13
JP21839294 1994-09-13
JP30380994A JP3337178B2 (ja) 1994-07-13 1994-12-07 クローバーイエローベインウイルスプロテアーゼ

Publications (1)

Publication Number Publication Date
MX9503070A true MX9503070A (es) 1997-01-31

Family

ID=27321781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9503070A MX9503070A (es) 1994-07-13 1995-07-13 Sistema de expresion que utiliza proteinas de fusion autolisables y un polipeptido de reduccion novedoso.

Country Status (14)

Country Link
US (3) US5955072A (es)
EP (2) EP1251176A3 (es)
KR (1) KR100417026B1 (es)
CN (4) CN1090676C (es)
AU (1) AU696358B2 (es)
CA (1) CA2153720A1 (es)
CZ (2) CZ293582B6 (es)
FI (1) FI953422A (es)
HU (2) HU0202280D0 (es)
IL (1) IL114582A0 (es)
MX (1) MX9503070A (es)
NO (1) NO952763L (es)
NZ (1) NZ272561A (es)
TW (1) TW459046B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904539D0 (sv) * 1999-12-10 1999-12-10 Alphahelix Ab Method and device for the handling of samples and reagents
FR2824334B1 (fr) * 2001-05-03 2003-10-10 Coletica Procede pour tester une substance eventuellement active dans le domaine de la lipolyse et son utilisation principalement cosmetique
ATE432347T1 (de) * 2002-06-24 2009-06-15 Exiqon As Methoden und systeme zur detektion und isolation von nucleinsäuresequenzen
WO2006121803A1 (en) 2005-05-05 2006-11-16 Sensient Flavors Inc. Production of beta-glucans and mannans
EP1910550A4 (en) 2005-07-21 2009-11-04 Abbott Lab MULTIGENIC EXPRESSION COMPRISING SORF CONSTRUCTS AND METHODS USING POLYPROTEINS, PRO-PROTEINS, AND PROTEOLYSIS
US20100035300A1 (en) * 2006-02-27 2010-02-11 Wang Andrew H-J Producing a Target Protein Using Intramolecular Cleavage by TEV Protease
US9206431B2 (en) * 2007-09-27 2015-12-08 Academia Sinica Kit for producing recombinant tag-cleavable fusion proteins via at least two different expression vectors allow protein production in two different species host cells
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
CN102812040A (zh) * 2009-10-30 2012-12-05 雅培制药有限公司 Sorf构建体和多基因表达

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059482T3 (es) * 1987-12-23 1994-11-16 Boehringer Ingelheim Int Expresion de la proteasa p2a de hrv2 codificada por virus.
US5162601A (en) * 1989-11-22 1992-11-10 The Upjohn Company Plant potyvirus expression vector with a gene for protease
US6077694A (en) * 1990-09-21 2000-06-20 The United States Of America As Represented By The Department Of Health And Human Services Method for over-expression and rapid purification of biosynthetic proteins
HU220098B (hu) * 1991-08-30 2001-10-28 Vertex Pharmaceuticals Incorporated Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok
AU1743795A (en) * 1994-02-03 1995-08-21 Scripps Research Institute, The A cassette to accumulate multiple proteins through synthesis of a self-processing polypeptide

Also Published As

Publication number Publication date
KR100417026B1 (ko) 2004-05-17
EP0700999A2 (en) 1996-03-13
EP1251176A2 (en) 2002-10-23
CN1320689A (zh) 2001-11-07
HUT72922A (en) 1996-06-28
AU696358B2 (en) 1998-09-10
NZ272561A (en) 1997-03-24
FI953422A0 (fi) 1995-07-13
EP0700999A3 (en) 1997-04-16
HU9502114D0 (en) 1995-09-28
CN1385529A (zh) 2002-12-18
EP1251176A3 (en) 2002-12-18
AU2497095A (en) 1996-01-25
TW459046B (en) 2001-10-11
CN1385532A (zh) 2002-12-18
US5955072A (en) 1999-09-21
NO952763L (no) 1996-01-15
CZ293582B6 (cs) 2004-06-16
CZ293745B6 (cs) 2004-07-14
CN1090676C (zh) 2002-09-11
US6743611B2 (en) 2004-06-01
CN1126759A (zh) 1996-07-17
HU0202280D0 (es) 2002-09-28
IL114582A0 (en) 1995-11-27
US20030176688A1 (en) 2003-09-18
NO952763D0 (no) 1995-07-12
CA2153720A1 (en) 1996-01-14
CZ180895A3 (en) 1996-02-14
FI953422A (fi) 1996-01-14
US6307038B1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
HU9601448D0 (en) Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
WO2001079507A3 (en) EXPRESSION-REGULATING SEQUENCES AND EXPRESSION PRODUCTS IN THE FIELD OF FILAMENTOUS FUNGI $i(CHRYSOSPORIUM)
CA2170515A1 (en) Nucleotide sequences for novel protein tyrosine phosphatases
DE69534600D1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
MX9503070A (es) Sistema de expresion que utiliza proteinas de fusion autolisables y un polipeptido de reduccion novedoso.
ATE90729T1 (de) Toxin-segment des kristallgens vom bacillus thuringiensis.
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
DK0870833T3 (da) Gener for ultrathermostabile proteaser
NZ527971A (en) Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
WO2000001831A3 (en) Proteases fused with variants of streptomyces subtilisin inhibitor
WO1998042827A3 (en) Gene encoding oxalate decarboxylase from aspergillus phoenicis
CA2253006A1 (en) .beta.-carotene hydroxylase gene
CO4480058A1 (es) Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa
DK1127064T3 (da) Hidtil ukendte aminosyresekvenser, DNA, der koder for aminosyresekvenserme, antistoffer, der er rettet mod sådanne sekvenser, og forskellige anvendelser deraf
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
RU97103147A (ru) Днк-последовательности, кодирующие человеческие протеины тх и ту, родственные конвергирующему интерлейкин-1-бета ферменту
EP0837074A3 (en) Biologically active fibronectin fragment as cancer metastasis inhibitor
WO2001049714A3 (en) Nope polypeptides, encoding nucleic acids and methods of use
EP0911408A3 (en) DNA coding for serine/threonine kinase
AU2640299A (en) Genomic gene encoding hm1.24 antigen protein and promoter thereof
Kostka et al. Isolation and molecular characteristics of avian pepsins
ES2161130A1 (es) Dna recombinante derivado del virus de la sharka y vector de expresion de proteinas heterologas basado en dicho dna recombinante.
CA2238668A1 (en) Novel enzyme catalyzing dephosphorylation
EP1371725A4 (en) NEW AMINOPEPTIDASE AND ITS GENE